Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/085—Angiotensins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, as well as to a method for prophylaxis and treatment of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure .
• Dyspepsia and irritable bowel syndrome are two of the most frequent health conditions encountered in the general population. Epidemiological studies have reported prevalence rates of 25-30% annually if restricted to those who have recurrent abdominal symptoms. The exact mechanisms behind functionally related complaints from the gastrointestinal tract are today unknown. It is believed that they depend on dyscoordination of the functional state in various segments along the gut
• acid-related dyspepsia One well-known group of dyspeptic symptoms is "acid- related".
• the definition of acid-related dyspepsia is that there occurs a symptom-relief when stomach acidity is lowered by use of antacids or antisecretagogues .
• a prerequisite for acid-related dyspeptic symptoms is that luminal acid gets access to the superficial mucosal cells where the sensory receptors are located. This is not the case during normal conditions, as a continuos transport of fluid and bicarbonate provides a neutral compartment at the mucosal surface. This important acid neutralisation on the mucosal surface is dependent on alkaline volume secretion and mixing transport of the luminal con- tents by co-ordinated intestinal wall movements. If the surface neutralisation process is down-regulated, e.g.
• mucosal acidification may occur allowing for perception of abdominal discomfort either due to direct activation of mucosal acid-receptors, or indirectly by changed wall motility registered by noci- ceptors in the muscle layers of the gut.
• drugs e.g. non-steriodal antiinflammatory drugs
• Dyspepsia due to peptic ulcers can be cured by intake or antacids and inhibitors of gastric acid secre- tion. Ulcer-like dyspeptic symptoms without known organic cause are usually sensitive to similar treatment.
• acid related dyspepsia is defined by the symptom- relief in association with the intake of neutralising agents or inhibition of gastric acid production by use of proton pump inhibitors or histamine type 2 receptor antagonists.
• the former principle is shortlasting and neutralising drugs must thus be administered repeat- 3 edly during the day.
• the latter drugs have disadvantages of being expensive and exert a great impact on the gut physiology as the anacid gastric conditions increase the risk for intestinal and/or systemic infections.
• Proki- netic drugs such as cisapride, modulating gut wall motility; anticholineric compounds inhibiting acid secretion and wall contractions; as well as prostglandine- analogues for preservation of mucosal integrity; are other principles that are utilised for dyspeptic symptoms and IBS, usually with low efficacy and high frequency of side effects. It follows that therapeutic regimens for treatment of functional disorders of the gut are largely lacking and those available are impaired by serious disadvantages . Another condition in which the intestinal mucosapro- tective functions are disturbed is multiple organ failure, MOF. Severe physical stress on the organism (life- threatening critical illness due to e.g.
• burn injuries or mechanical multitrauma elicits a vasoregulatory response associated with down-regulation of the functional state of non-vital organs, preferentially the mesenteric organs.
• Distorted mucosa-protective functions are associ ⁇ ated with acid-dependent gastric erosions and bleedings ("haemorrhaged stress-gastritis") and enables gut patho- gens to cross the intestinal mucous and penetrate the mucosal epithelium to eventually spread to systemic compartments via lymphatic and blood vessels. The latter may have severe consequences as the microbial translocation elicits a systemic inflammatory response which, together with the initially compromised systemic circulation, leads to functional failure of various distant organs, e.g.
• MOF multiple organ failure
• the treatment of multiple organ failure is very costly and results in long term treatments at intensive care units.
• Therapeutic efforts in MOF treatment today 4 are mainly aimed at lifesustaimng treatments, such as administration of antibiotics, volume expansion and respiratory assistance.
• the development of MOF is a mucosal barrier dysfunction and it follows that therapeutic strategies that support mucosaprotective functions of the gut may improve or prevent the condition.
• the renin-angiotensin system is a regulatory axis, which primarily is involved m circulation homeostasis but has also large impact on gut functions.
• Angiotensin II is a polypeptide, more specifically an octapeptide, occurring m the sera of mammals, including humans. It is a hormone released when the mammal is sub- jected to stress, and it has a vasoconstrictive and thus blood pressure-raising effect. It also stimulates the secretion of aldosterone from the adrenal glands, which contributes to the blood pressure-raising effect. It is produced m the remn-angiotensm-aldosterone system by conversion of angiotensin I under the influence of the angiotensm-convertmg enzyme, ACE.
• ACE angiotensm-convertmg enzyme
• angiotensin II receptor subtypes Although the existence of angiotensin II receptor subtypes has been suspected for some time, definite evidence for angiotensin II receptor heterogeneity has been obtained only with the recently introduced non-peptide angiotensin II receptor antagonists, exemplified with the prototypic compounds DuP 753 (losartan) and PD 123177.
• the sites having high affinity for DuP 753 are designated as site 1 - angiotensin II type 1 receptors - and those having high affinity for PD 123177 as site 2 - angiotensin II type 2 receptors.
• the function of angiotensin II type 2 receptors has been unidentified m spite of numerous investigations.
• angiotensin II-type 2 receptors Activation of angiotensin II-type 2 receptors are involved in the reduction of mesenteric blood flow and the decreased mucosaprotective functional state during various stress conditions.
• one possible way to pre- 5 vent dyspeptic symptoms and MOF is to block the formation of angiotensin II. This may be done by administration of angiotensin converting enzyme inhibitors (ACE- mhibitors), i.e. compounds that block the formation of angiotensin II. This method has for example been shown to improve mesenteric oxygenation during severe shock.
• ACE- mhibitors angiotensin converting enzyme inhibitors
• ACE-mhibitors for treatment of gut disorders is, however, hampered by the fact that they are acting as non-specific enzyme inhibitors, resulting in accumulation of several vasoactive peptides, e.g. brady- kimn, substance P, and endogenous opoids . This may lead to mstable blood pressure regulation as well as an increased risk for allergic manifestations and upper airway irritation.
• Another way to prevent MOF is to block the angiotensin II type 1 receptors. This is known from the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8), wherein the use of angiotensin II type 1 receptor antago&ists for treatment and prophylaxis of MOF is described.
• the effect of these agonists is a pharmacological specific blockade of angiotensin II type 1 receptors resulting m an increase of gastrointestinal tissue oxygenation in turn reinforcing the mucosal barrier function in the upper gastrointestinal tract.
• the object of the invention is to provide a pharmaceutical preparation as well as a method for treatment of condition affecting the alimentary tract, such as dyspep- sia, irritable bowel syndrome or multiple organ failure.
• the invention is based on a new, until now unknown functional role for a subclass of angiotensin II receptors. Selective stimulation of angiotensin II type 2 receptors has been found to elicit a profound activation of gastroduodenal mucosal alkaline secretion and gut motility, effects which lead to a strengthening of the intestinal mucous membrane, thus counteracting conditions of 6 the alimentary tract, such as dyspepsia, irritable bowel syndrome or by multiple organ failure.
• the present invention relates to a pharmaceutical preparation comprising at least one angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof.
• the invention also relates to use of an angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof for the manufacture of a medicament for treatment and/or prophylaxis of a disorder of the alimentary tract, such as dyspepsia, or of multiple organ failure .
• the invention relates to a method for treatment and/or prevention of an affection selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and/or multiple organ failure in a patient, characterised in that an effective amount of at least one angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof is administered to the patient.
• angiotensin II type 2 receptor agonist used herein relates to any compound binding specifically to, and thus stimulating, angiotensin II type 2 receptors .
• patient used herein relates to all kinds of mammals, including humans, in need of treatment and/or prophylaxis according to the invention.
• an angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof may be any substance, derived from natural sources or from synthesis by chemical and/or genetic en- 7 gineering methods, functioning as an angiotensin II type 2 receptor agonist.
• the agonist may be either a peptide or a peptide mimetic with high selectivity for the angiotensin II type 2 receptor.
• Examples of peptides functioning as angiotensin II type 2 receptor agonist and thus suitable for use according to the present invention are p-aminophenylalanine 6 - angiotensin II or N- ⁇ -nicotinoyl-Tyr- (N- ⁇ -CBZ-Arg) -Lys- His-Pro-Ile-OH.
• p-aminophenylalanine 6 -angiotensin II is used, it is preferably administered to the patient directly into the blood. This peptid has a short length of life and will therefore only have an effect for a limited time. This enables an easy control of the effects.
• a peptide mi- metic may contain elements that enforce steric constraints of a peptide and a peptide mimetic may retain some peptidic character.
• a peptide mimetic may alternatively be lacking peptidic fragments and consist of an organic molecule.
• a peptide mimetic can be an organic molecule comprising biaryl, arylheteroaryl, or biheteroaryl fragments that can be attached to a nitrogen containing monocyclic or bicyclic heterocycle by a one, two or three atom linker.
• a selective angiotensin II type 2 receptor agonist may be an analogue of the non- selective angiotensin II type 2 receptor ligand 5,7- dimethyl-2-ethyl-3- [ [4- [2 (n-butyloxycarbonylsulfonamido) - 5-isobutyl-3-thienyl] phenyl] methyl] -imidazo [4 , 5-b] - pyridine
• angiotensin II type 2 agonist it is preferable to use a selective angiotensin II type 2 agonist.
• non- selective angiotensin II type 2 agonists In order to block the negative effects that these non-selective ago- nists may cause due to their influence on the angiotensin II type 1 receptor, it is suitable to combine them with a angiotensin II type 1 receptor antagonist m order to block the angiotensin II type 1 receptor.
• angio- tensm II type 1 receptor antagonists are known m the art; examples of suitable substances are e.g. described m the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8).
• the pharmaceutical preparations according to the m-vention may be any kind of conventionally used preparations.
• the pharmaceutical preparations according to the invention may comprise other substances such as e.g. physiologically acceptable additives, such as a solvent, an adjuvant, a carrier and/or a suitable preservative.
• the pharmaceutical preparations according to the invention have the form of solutions for injection, but they may also be e.g. solutions, suspensions, tablets or capsules intended for oral, sublmgual or rectal ad- ministration.
• the pharmaceutical preparations according to the invention are particularly useful for prophylaxis and/or treatment of multiple organ failure, dyspepsia and other disorders affecting the alimentary tract. According to the present invention it is thus possible to treat and/or prevent disorders of the alimentary tract or gastrointestinal disorders.
• disorders include xerostomia, gastro-oesophageal reflux disease, oesophagitis, gastritis, gastroparesis, gastro- duodenal ulcer disease, non ulcer dyspepsia, hyperacidity, pancreatitis, disorders of the biliary tract, coe- liacia, Crohn' s disease, ulcerative colitis, diarrhoea, constipation, irritable bowel disease, colic, dysphagia, obesitas, vomiting, nausea, indigestion and S ogren's syndrome.
• Example 1 In this m-vivo example, the angiotensin II type 2 receptor agonist p-am ⁇ nophenylalan ⁇ ne 6 -ang ⁇ otensm II, a peptide obtained from SIGMA (Product No. A1811), was used. This agonist was administered intravenously to a chloralose-anesthetized rat prepared for m-situ titra- tion of duodenal mucosal alkaline secretion (the methodological is described by Flemstrom et al in Am. J. Physiol. 1982, 243: G348). It was found that increasing infusion rates of the compound stimulated markedly the mucosal alkalinisation m a dose-dependent fashion, which is illustrated m the table below.
• the selective angiotensin II type 2 receptor agonist CGP 42112A N- ⁇ -nicotinyl-Tyr- (N- -CZB-Arg) Lys-His-Pro-Ile-OH
• This agonist was administered intravenously to chlora- lose-anaesthetised rats prepared for in-situ titration as described in Example 1.
• CGP 42112A was also administered together with a specific angiotensin II type 2 receptor antagonist PD123319 (200 ⁇ g/kg intravenously) .
• PD123319 a specific angiotensin II type 2 receptor antagonist
• Example 3 In this in-vivo example, the endogenous ligand of angiotensin II receptors, Angiotensin II, obtained from SIGMA, was used. This agonist was administered intravenously to chloralose-anaesthetised rats prepared for in- situ titration as described in Example 1. It was found that angiotensin II given alone did not increase the duodenal mucosal alkaline secretion, as shown in table 3 below.
• angiotensin II type 1 receptor antagonist losartan 10 mg/kg intrave- nously
• angiotensin II infusion stimulated duodenal mucosal alkaline secretion, as evident from the table.
• L-162,313 infusion (0.3 mg/kg bolus injection i.v., followed by continuos infusion of 0.03 mg/kg x h) increased duodenal mucosal alkaline secretion by 86% compared to baseline.

Applications Claiming Priority (3)

Publications (1)

Family

ID=20410283

Family Applications (1)

Country Status (18)

Families Citing this family (28)

Family Cites Families (5)

• 1998
  • 1998-02-24 SE SE9800550A patent/SE9800550D0/xx unknown
• 1999
  • 1999-02-24 EP EP99908017A patent/EP1066048A1/en not_active Withdrawn
  • 1999-02-24 NZ NZ506188A patent/NZ506188A/xx unknown
  • 1999-02-24 ID IDW20001909A patent/ID26639A/id unknown
  • 1999-02-24 JP JP2000533135A patent/JP2002504516A/ja active Pending
  • 1999-02-24 BR BR9908188-1A patent/BR9908188A/pt not_active IP Right Cessation
  • 1999-02-24 IL IL13799099A patent/IL137990A0/xx unknown
  • 1999-02-24 HU HU0101411A patent/HUP0101411A3/hu unknown
  • 1999-02-24 CA CA002319123A patent/CA2319123A1/en not_active Abandoned
  • 1999-02-24 KR KR1020007009295A patent/KR20010041211A/ko not_active Application Discontinuation
  • 1999-02-24 WO PCT/SE1999/000262 patent/WO1999043339A1/en not_active Application Discontinuation
  • 1999-02-24 AU AU27537/99A patent/AU755949B2/en not_active Ceased
  • 1999-02-24 CN CN99803230A patent/CN1291104A/zh active Pending
  • 1999-02-24 MX MXPA00008172A patent/MXPA00008172A/es unknown
  • 1999-02-24 EE EEP200000481A patent/EE200000481A/xx unknown
  • 1999-02-24 SK SK1152-2000A patent/SK11522000A3/sk unknown
• 2000
  • 2000-08-21 IS IS5594A patent/IS5594A/is unknown
  • 2000-08-23 NO NO20004215A patent/NO20004215L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events